Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
April 16, 2024 08:30 ET
|
Palisade Bio, Inc.
Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI)...
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
February 15, 2024 08:35 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
Luigi Franciosi to Advise on New Asthma & COPD Drug Development Programs for Vicenna Pharmaceuticals Inc.
January 07, 2020 12:30 ET
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Franciosi Consulting Ltd. (“FCL”) is pleased to announce that its President and CEO, Dr. Luigi Franciosi, has been retained as a...